THE LANCET, Vol 355, February 26, 2000 George Perry, Akihiko Nunomura, Arun K Raina, Mark A Smith View Poster Post navigationPreviousPrevious post:Neuroactive neurosteroids as endogenous effectors for the sigma1 (σ1) receptor: Pharmacological evidence and therapeutic opportunities.NextNext post:Sigma-1 receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine affords neuroprotection from focal ischemia with prolonged reperfusion.Related PostsAnavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s DiseaseJanuary 11, 2021Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect ConferenceJanuary 6, 2021Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesDecember 28, 2020Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020December 22, 2020
Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s DiseaseJanuary 11, 2021
Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesDecember 28, 2020
Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020December 22, 2020
